Patents by Inventor Bryan A. Irving

Bryan A. Irving has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-PD-L1 antibodies, compositions and articles of manufacture
    Patent number: 9920123
    Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: March 20, 2018
    Assignee: Genentech, Inc.
    Inventors: Bryan Irving, Henry Chiu, Heather Maecker, Sanjeev Mariathasan, Sophie M. Lehar, Yan Wu, Jeanne Cheung
  • Methods of treating cancer using PD-L1 axis binding antagonists and VEGF antagonists
    Patent number: 9895441
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist, chemotherapy and optionally a VEGF antagonist and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: February 20, 2018
    Assignee: GENENTECH, INC.
    Inventors: Heather Maecker, Bryan Irving
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS
    Publication number: 20180021431
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Application
    Filed: June 28, 2017
    Publication date: January 25, 2018
    Applicant: Genentech, Inc.
    Inventors: Heather MAECKER, Bryan IRVING
  • Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
    Patent number: 9873740
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: January 23, 2018
    Assignee: Genentech, Inc.
    Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
  • Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
    Patent number: 9724413
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Grant
    Filed: August 1, 2012
    Date of Patent: August 8, 2017
    Assignee: Genentech, Inc.
    Inventors: Heather Maecker, Bryan Irving
  • METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION TO TREAT TUMOR IMMUNITY
    Publication number: 20170107287
    Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: October 26, 2016
    Publication date: April 20, 2017
    Applicant: Genentech, Inc.
    Inventors: Bryan IRVING, Henry CHIU, Heather MAECKER, Sanjeev MARIATHASAN, Sophie M. LEHAR, Yan WU, Jeanne CHEUNG
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
    Publication number: 20170044256
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Application
    Filed: August 17, 2016
    Publication date: February 16, 2017
    Inventors: Jane GROGAN, Robert J. JOHNSTON, Bryan IRVING, Jason HACKNEY, Xin YU, Dan EATON, Kristin BOWLES, Laetitia COMPS-AGRAR
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
    Publication number: 20170037127
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Application
    Filed: August 17, 2016
    Publication date: February 9, 2017
    Inventors: Jane GROGAN, Robert J. JOHNSTON, Bryan IRVING, Jason HACKNEY, Xin YU, Dan EATON, Kristin BOWLES, Laetitia COMPS-AGRAR
  • METHODS OF TREATING HER2-POSITIVE CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-HER2 ANTIBODIES
    Publication number: 20170008971
    Abstract: The invention provides compositions and methods for treating HER2-postitive cancers. The method comprising administering a PD-1 axis binding antagonist and an antibody that targets HER2.
    Type: Application
    Filed: June 16, 2016
    Publication date: January 12, 2017
    Applicant: Genentech, Inc.
    Inventors: Mark S. DENNIS, Allen EBENS, Bryan IRVING, Teemu T. JUNTTILA, Ji LI
  • NUCLEIC ACID ENCODING ANTI-PD-L1 ANTIBODIES
    Publication number: 20160222117
    Abstract: The present application relates to nucleic acid encoding anti-PD-L1 antibodies, which have therapeutic use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: September 4, 2015
    Publication date: August 4, 2016
    Applicant: GENENTECH, INC.
    Inventors: Bryan IRVING, Henry CHIU, Heather MAECKER, Sanjeev MARIATHASAN, Sophie M. LEHAR, Yan WU, Jeanne CHEUNG
  • METHODS OF TREATING CANCER USING PD-L1 AXIS BINDING ANTAGONISTS AND VEGF ANTAGONISTS
    Publication number: 20150320859
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist, chemotherapy and optionally a VEGF antagonist and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Application
    Filed: December 1, 2014
    Publication date: November 12, 2015
    Applicant: GENENTECH, INC.
    Inventors: Heather MAECKER, Bryan IRVING
  • ANTI-PD-L1 ANTIBODIES AND ARTICLES OF MANUFACTURE
    Publication number: 20150322153
    Abstract: The present application relates to anti-PD-L1 antibodies, which have therapeutic use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: November 11, 2014
    Publication date: November 12, 2015
    Applicant: GENENTECH, INC.
    Inventors: Bryan IRVING, Henry CHIU, Heather MAECKER, Sanjeev MARIATHASAN, Sophie M. LEHAR, Yan WU, Jeanne CHEUNG
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
    Publication number: 20150216970
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Application
    Filed: July 16, 2014
    Publication date: August 6, 2015
    Inventors: Jane GROGAN, Robert J. JOHNSTON, Bryan IRVING, Jason HACKNEY, Xin YU, Dan EATON, Kristin BOWLES, Laetitia COMPS-AGRAR
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS
    Publication number: 20140341902
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Application
    Filed: August 1, 2012
    Publication date: November 20, 2014
    Applicant: Genentech, Inc.
    Inventors: Heather Maecker, Bryan Irving
  • METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION TO TREAT TUMOR IMMUNITY
    Publication number: 20140065135
    Abstract: The present application relates to methods of using anti-PD-L1 antibodies to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: July 30, 2013
    Publication date: March 6, 2014
    Applicant: Genentech, Inc.
    Inventors: Bryan Irving, Henry Chiu, Heather Maecker, Sanjeev Mariathasan, Sophie M. Lehar, Yan Wu, Jeanne Cheung
  • METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION TO TREAT TUMOR IMMUNITY
    Publication number: 20130045201
    Abstract: The present application relates to methods of using anti-PD-L1 antibodies to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: May 23, 2012
    Publication date: February 21, 2013
    Applicant: Genentech, Inc.
    Inventors: BRYAN IRVING, HENRY CHIU, HEATHER MAECKER, SANJEEV MARIATHASAN, SOPHIE M. LEHAR, YAN WU, JEANNE CHEUNG
  • ANTI-PD-L1 ANTIBODIES AND ARTICLES OF MANUFACTURE
    Publication number: 20130045202
    Abstract: The present application relates to anti-PD-L1 antibodies, which have therapeutic use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: May 24, 2012
    Publication date: February 21, 2013
    Applicant: Genentech, Inc.
    Inventors: Bryan Irving, Henry Chiu, Heather Maecker, Sanjeev Mariathasan, Sophie M. Lehar, Yan Wu, Jeanne Cheung
  • METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO TREAT INFECTION RESULTING FROM T-CELL DYSFUNCTION
    Publication number: 20130045200
    Abstract: The present application relates to methods of using anti-PD-L1 antibodies to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: May 23, 2012
    Publication date: February 21, 2013
    Applicant: Genentech, Inc.
    Inventors: Bryan Irving, Henry Chiu, Heather Maecker, Sanjeev Mariathasan, Sophie M. Lehar, Yan Wu, Jeanne Cheung
  • Anti-PD-L1 antibodies, compositions and articles of manufacture
    Patent number: 8217149
    Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: July 10, 2012
    Assignee: Genentech, Inc.
    Inventors: Bryan Irving, Henry Chiu, Heather Maecker, Sanjeev Mariathasan, Sophie M. Lehar, Yan Wu, Jeanne Cheung
  • NOVEL GENE DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO
    Publication number: 20110182883
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO218, PRO228, PRO271, PRO273, PRO295, PRO302, PRO305, PRO326, PRO386, PRO655, PRO162, PRO788, PRO792, PRO940, PRO941, PRO1004, PRO1012, PRO1016, PRO474, PRO5238, PRO1069, PRO1111, PRO1113, PRO1130, PRO1195, PRO1271, PRO1865, PRO1879, PRO3446, PRO3543, PRO4329, PRO4352, PRO5733, PRO9859, PRO9864, PRO9904, PRO9907, PRO10013, PRO90948, PRO28694, PRO16089, PRO19563, PRO19675, PRO20084, PRO21434, PRO50332, PRO38465 or PRO346 genes.
    Type: Application
    Filed: March 3, 2011
    Publication date: July 28, 2011
    Inventors: Katherin E. Combs, Frederic de Sauvage, Liangfen Fan, Ellen Filvaroff, Allison Anne Byers Horner, Bryan Irving, Jagath Reddy Junutula, Erin Marie Massey, Dina Rebecca Mclain, Laurie Jeanette Minze, Charles Montgomery, Bobby Joe Payne, Heidi Phillips, Carolina Rangel, Tracy Ellen Willis Sevaux, Zheng-Zheng Shi, Mary Jean Sparks, Joy Anne Stala, Teresa Gail Townsend, Peter Vogel